Health

New Vaccine From Pfizer Protects Newborn From Severe Illness?

On Tuesday, November 1, Pfizer stated that their RSV vaccine for pregnant women provides at least 6 months of protection against severe illnesses in babies.

The vaccine prevented severe RSV cases in newborns whose mothers were vaccinated by 82% in phase III of a randomized, double-blind, and placebo-controlled research.

For your information, RSV is a common virus that affects the lungs. It makes people like they have a mild cold. Even though most kids and adults who are infected with RSV get better without any major long-term effects, Chang said that the virus could be serious and even kill babies, young kids, and older adults.

This protection lasts from birth until 3 months. Pfizer added that the vaccination was 69% effective at 6 months of age, despite a decrease in protection.

According to Yahoo News, participants in the trial were monitored for six months following vaccination to determine the vaccine’s safety and effectiveness. Moreover, the infants were monitored for at least a year, and more than half were monitored for two years.

“As someone who spent part of their ID training focused on RSV research, this is wonderful news,”

— Dr. Michael Chang, pediatric infectious diseases specialist

Dr. Chang also said that the vaccination might be a “game changer”, but they must consider other things as well. This includes children older than 1 year who have a high disease burden.

RSV mortality is highest among premature infants and newborns who have cyanotic congenital heart disease.  This immunization may not assist these patients, he added.

Chang emphasized that maternal immunization for pertussis (whooping cough) has been utilized successfully in the past. In addition, new results indicate that mothers who get COVIDvaccinations during pregnancy can likewise convey protective antibodies to their infants.

Pfizer’s plan

Pfizer plans to test the vaccine in pregnant women, younger individuals, and elderly people who are at risk for serious infection. In August, the company revealed positive vaccination trial results in older adults.

Pfizer has stated that it intends to submit a licensing application to the FDA before the year’s end. Vaccine distribution is anticipated for late 2023 or early 2024 if it receives regulatory approval.

Source: Yahoo News, NBC News

Adib Mohd

Recent Posts

TV Sarawak Is Leveling Up, From Kuching to the World with Spotlight 25/26

Since its debut in 2020, TV Sarawak (TVS) has been rewriting what it means to… Read More

7 hours ago

Skechers Steps Up the Game with New Basketball Collection

Skechers, The Comfort Technology Company™ and a global leader in lifestyle and performance footwear, has… Read More

7 hours ago

LexisNexis Brings AI Legal Sidekick to Malaysia with Protégé

Move over Suits, the future of law just got an AI upgrade. LexisNexis has officially… Read More

8 hours ago

BJAK Turns Insurance Renewals into Rewards with RM100,000 Mega Giveaway This 10.10

Renewing insurance and road tax is often a last-minute hassle, but BJAK, Malaysia’s largest online… Read More

12 hours ago

SHANTEA Dessert Opens First Outlet at Mid Valley, Serving Malaysian Culture Through Sweet Creations Ahead of Visit Malaysia 2026

Malaysian flavors stepped into the spotlight today as SHANTEA Dessert officially opened its first outlet… Read More

13 hours ago

Energea Powers Up Malaysia with Bold Tangerine Collection and Next-Gen Hybrid-Solid State Powerbank

Energea, the lifestyle-driven power solutions and tech accessories brand, has officially introduced two groundbreaking innovations:… Read More

13 hours ago

This website uses cookies.